THERAVANCE BIOPHARMA INC (TBPH) — insider trading
Health Care · NASDAQ
THERAVANCE BIOPHARMA INC (TBPH) has 103 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 100 (latest 2026-09-23).
Recent Form 4 transactions
Showing the 100 most recent of 103 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Weiss Asset Management LP; WEISS ANDREW M; WAM GP LLC | Other | Other acquisition or disposition | 7,457,060 | $17.00 | $126.77M | Form 4 |
| 2026-09-23 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Disposition to the issuer (derivative) | 515,000 | — | — | Form 4 |
| 2026-09-23 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Disposition to the issuer | 92,567 | — | — | Form 4 |
| 2026-09-23 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Disposition to the issuer | 23,400 | — | — | Form 4 |
| 2026-09-23 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Disposition to the issuer | 76,875 | — | — | Form 4 |
| 2026-09-23 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Disposition to the issuer | 151,875 | — | — | Form 4 |
| 2026-09-23 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Disposition to the issuer | 1,382,272 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 13,398 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 24,258 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 23,576 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 22,044 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 28,000 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer (derivative) | 13,500 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer | 6,009 | — | — | Form 4 |
| 2026-09-23 | Smaldone Alsup Laurie | Director | Disposition to the issuer | 74,980 | — | — | Form 4 |
| 2026-09-23 | Sawaf Aziz | Officer (SVP & CHIEF FINANCIAL OFFICER) | Disposition to the issuer | 23,439 | — | — | Form 4 |
| 2026-09-23 | Sawaf Aziz | Officer (SVP & CHIEF FINANCIAL OFFICER) | Disposition to the issuer | 108,436 | — | — | Form 4 |
| 2026-09-23 | Sawaf Aziz | Officer (SVP & CHIEF FINANCIAL OFFICER) | Disposition to the issuer | 204,966 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer (derivative) | 13,398 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer (derivative) | 24,258 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer (derivative) | 23,576 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer (derivative) | 22,044 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer (derivative) | 28,000 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer (derivative) | 17,000 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer | 6,009 | — | — | Form 4 |
| 2026-09-23 | PAKIANATHAN DEEPIKA | Director | Disposition to the issuer | 58,065 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 13,398 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 24,258 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 23,576 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 22,044 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 28,000 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer | 6,009 | — | — | Form 4 |
| 2026-09-23 | O'Connor Donal | Director | Disposition to the issuer | 74,204 | — | — | Form 4 |
| 2026-09-23 | Miller Aine | Officer (SVP, DEV & HEAD OF IRE OFFICE) | Disposition to the issuer (derivative) | 37,500 | — | — | Form 4 |
| 2026-09-23 | Miller Aine | Officer (SVP, DEV & HEAD OF IRE OFFICE) | Disposition to the issuer | 96,718 | — | — | Form 4 |
| 2026-09-23 | Miller Aine | Officer (SVP, DEV & HEAD OF IRE OFFICE) | Disposition to the issuer | 93,108 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 13,398 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 24,258 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 23,576 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 22,044 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 28,000 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer (derivative) | 6,000 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer | 6,009 | — | — | Form 4 |
| 2026-09-23 | MITCHELL DEAN J | Director | Disposition to the issuer | 91,204 | — | — | Form 4 |
| 2026-09-23 | Grimaud Brett A. | Officer (SVP, GEN COUNSEL AND SECRETARY) | Disposition to the issuer | 23,439 | — | — | Form 4 |
| 2026-09-23 | Grimaud Brett A. | Officer (SVP, GEN COUNSEL AND SECRETARY) | Disposition to the issuer | 107,812 | — | — | Form 4 |
| 2026-09-23 | Grimaud Brett A. | Officer (SVP, GEN COUNSEL AND SECRETARY) | Disposition to the issuer | 223,917 | — | — | Form 4 |
| 2026-09-23 | GRAY SUSANNAH | Director | Disposition to the issuer (derivative) | 13,398 | — | — | Form 4 |
| 2026-09-23 | GRAY SUSANNAH | Director | Disposition to the issuer (derivative) | 24,258 | — | — | Form 4 |
| 2026-09-23 | GRAY SUSANNAH | Director | Disposition to the issuer (derivative) | 23,576 | — | — | Form 4 |
| 2026-09-23 | GRAY SUSANNAH | Director | Disposition to the issuer (derivative) | 22,044 | — | — | Form 4 |
| 2026-09-23 | GRAY SUSANNAH | Director | Disposition to the issuer (derivative) | 32,666 | — | — | Form 4 |
| 2026-09-23 | GRAY SUSANNAH | Director | Disposition to the issuer | 6,009 | — | — | Form 4 |
| 2026-09-23 | GRAY SUSANNAH | Director | Disposition to the issuer | 42,137 | — | — | Form 4 |
| 2026-09-23 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Disposition to the issuer (derivative) | 150,000 | — | — | Form 4 |
| 2026-09-23 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Disposition to the issuer | 89,062 | — | — | Form 4 |
| 2026-09-23 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Disposition to the issuer | 124,414 | — | — | Form 4 |
| 2026-09-15 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Open-market sale | 6,657 | $17.03 | $113.4K | Form 4 |
| 2026-09-15 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Open-market sale | 3,328 | $17.03 | $56.7K | Form 4 |
| 2026-09-15 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Open-market sale | 3,329 | $17.03 | $56.7K | Form 4 |
| 2026-08-20 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for taxes / exercise cost | 20,034 | $16.95 | $339.6K | Form 4 |
| 2026-08-20 | Sawaf Aziz | Officer (SVP & CHIEF FINANCIAL OFFICER) | Shares withheld for taxes / exercise cost | 8,112 | $16.95 | $137.5K | Form 4 |
| 2026-08-20 | Miller Aine | Officer (SVP, DEV & HEAD OF IRE OFFICE) | Shares withheld for taxes / exercise cost | 6,258 | $16.95 | $106.1K | Form 4 |
| 2026-08-20 | Grimaud Brett A. | Officer (SVP, GEN COUNSEL AND SECRETARY) | Shares withheld for taxes / exercise cost | 7,952 | $16.95 | $134.8K | Form 4 |
| 2026-08-20 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Shares withheld for taxes / exercise cost | 5,667 | $16.95 | $96.1K | Form 4 |
| 2026-07-01 | Samaha Eli | 10% owner | Open-market sale | 37,799 | $17.00 | $642.6K | Form 4 |
| 2026-06-30 | Samaha Eli | 10% owner | Open-market sale | 25,027 | $17.13 | $428.8K | Form 4 |
| 2026-06-29 | Samaha Eli | 10% owner | Open-market sale | 273,871 | $17.23 | $4.72M | Form 4 |
| 2026-06-19 | Miller Aine | Officer (SVP, DEV & HEAD OF IRE OFFICE) | Grant / award / vesting | 18,750 | — | $0 | Form 4 |
| 2026-06-15 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Open-market sale | 6,657 | $16.39 | $109.1K | Form 4 |
| 2026-06-15 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Open-market sale | 3,328 | $16.38 | $54.5K | Form 4 |
| 2026-06-15 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Open-market sale | 3,329 | $16.39 | $54.6K | Form 4 |
| 2026-06-12 | PAKIANATHAN DEEPIKA | Director | Grant / award / vesting (derivative) | 13,398 | — | $0 | Form 4 |
| 2026-06-12 | PAKIANATHAN DEEPIKA | Director | Grant / award / vesting | 6,009 | — | $0 | Form 4 |
| 2026-06-12 | O'Connor Donal | Director | Grant / award / vesting (derivative) | 13,398 | — | $0 | Form 4 |
| 2026-06-12 | O'Connor Donal | Director | Grant / award / vesting | 6,009 | — | $0 | Form 4 |
| 2026-06-12 | MITCHELL DEAN J | Director | Grant / award / vesting (derivative) | 13,398 | — | $0 | Form 4 |
| 2026-06-12 | MITCHELL DEAN J | Director | Grant / award / vesting | 6,009 | — | $0 | Form 4 |
| 2026-06-12 | GRAY SUSANNAH | Director | Grant / award / vesting (derivative) | 13,398 | — | $0 | Form 4 |
| 2026-06-12 | GRAY SUSANNAH | Director | Grant / award / vesting | 6,009 | — | $0 | Form 4 |
| 2026-06-12 | Smaldone Alsup Laurie | Director | Grant / award / vesting (derivative) | 13,398 | — | $0 | Form 4 |
| 2026-06-12 | Smaldone Alsup Laurie | Director | Grant / award / vesting | 6,009 | — | $0 | Form 4 |
| 2026-05-20 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Shares withheld for taxes / exercise cost | 5,678 | $16.55 | $94.0K | Form 4 |
| 2026-05-20 | Grimaud Brett A. | Officer (SVP, GEN COUNSEL AND SECRETARY) | Shares withheld for taxes / exercise cost | 8,829 | $16.55 | $146.1K | Form 4 |
| 2026-05-20 | Miller Aine | Officer (SVP, DEV & HEAD OF IRE OFFICE) | Shares withheld for taxes / exercise cost | 6,827 | $16.55 | $113.0K | Form 4 |
| 2026-05-20 | Sawaf Aziz | Officer (SVP & CHIEF FINANCIAL OFFICER) | Shares withheld for taxes / exercise cost | 8,670 | $16.55 | $143.5K | Form 4 |
| 2026-05-20 | Winningham Rick E | Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for taxes / exercise cost | 20,038 | $16.55 | $331.6K | Form 4 |
| 2026-04-01 | Farnum Rhonda | Officer (SVP, COMM & MEDICAL AFFAIRS) | Grant / award / vesting | 18,750 | — | $0 | Form 4 |
Ask the chat about TBPH's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: THERAVANCE BIOPHARMA INC (TBPH).
Last updated 2026-09-23 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.